Cargando…
Severe hypereosinophilic syndrome successfully treated with a monoclonal antibody against interleukin 5 receptor α – benralizumab
Hypereosinophilic syndrome (HES) is a group of a rare diseases characterized by marked eosinophilia in blood or tissue and eosinophil-related clinical manifestations. Benralizumab is a humanized, monoclonal antibody against interleukin 5 (IL-5) receptor α, which is expressed on human eosinophils. He...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Termedia Publishing House
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8574116/ https://www.ncbi.nlm.nih.gov/pubmed/34764813 http://dx.doi.org/10.5114/ceji.2021.108259 |